Two clarifications here. First, based upon past precedence of other recent CVOTs, the top line data announcement will not state the RRR. The RRR will come later at full data set presentation. Second, there is not a minimum %RRR needed to pass the trial. Passing the trial is based upon achieving a statistical difference between placebo and apabetalone groups for time to first occurrence in 3-point MACE. Although the probability of statistical success improves with a larger apabetalone effect, a %RRR less than the arbitrary 30% will still count as a trial success if the two groups are found to be statistically different. So it is important to dintinguish between a statistical success and a practical success.
BearDownAZÂ
